PRPH
ProPhase Labs, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.01
−3.75%Year over year
Reported trailing growth
- Revenue
- -5.5%
- EBITDA
- +72.3%
- EBIT
- +47.6%
- EPS
- +83.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +2327.0%
- EBITDA
- —
- EPS
- +398.1%
Three-year CAGR
- Revenue
- -67.2%
- EBITDA
- +64.8%
- EBIT
- +53.3%
- Net income
- +72.4%
- EPS
- +93.3%
- Free cash flow
- +54.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026